There is one clinical trial.
The purpose of this study is to assess the safety and efficacy of merimepodib (MMPD) oral solution when administered in combination with remdesivir in adult patients with advanced COVID-19.
Description: Proportion of subjects alive at Day 28 who are not hospitalized or if hospitalized are free of respiratory failureMeasure: Number of subjects not hospitalized or, if hospitalized, free of respiratory failure Time: Day 0 to Day 28
Description: Number of Adverse Events (AEs) and number & percentage of subjects experiencing AEs after administration of the first dose of study drugMeasure: Adverse Events Time: Day 0 to Day 56
Description: Change in NIAID 8-point ordinal scale, where 1=Death and 8=Not hospitalized, no limitations on activitiesMeasure: National Institute of Allergy and Infectious Disease (NIAID) 8-Point Ordinal Scale Time: Day 0 to Day 28
Description: Duration of feverMeasure: Temperature Time: Day 0 to Day 37
Description: Number of deathsMeasure: Death Time: Day 0 to Day 56
Description: Need and duration of mechanical ventilationMeasure: Mechanical ventilation Time: Day 0 to Day 56
Description: Duration of vasopressor supportMeasure: Vasopressor Support Time: Day 0 to Day 56
Description: Duration of oxygen therapy via mechanical ventilation, face mask or nasal cannulaMeasure: Oxygen Therapy Time: Day 0 to Day 37
Description: Time to cessation of viral shedding based on absence of SARS-CoV-2 in a PCR based COVID-19 testMeasure: Cessation of Viral Shedding Time: Day 0 to Day 37
Description: Change in SpO2/FiO2Measure: Change in Oxygen Saturation/Fraction of Inspired Oxygen Time: Day 0 to Day 37
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports